The rare, deadly blood clots triggered by an autoimmune response to the COVID-19 vaccines from Johnson & Johnson and ...

Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while ...

The FDA has approved two diagnostic devices that allow women to collect vaginal samples themselves for cervical cancer ...

On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible ...

Atai Life Sciences, one of the leading shareholders in psilocybin drug developer Compass Pathways, is swapping CEOs.

After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a ...

OnKure Therapeutics has merged with Reneo Pharmaceuticals, jumping onto Wall Street with $120 million and a lead breast ...

Results from the phase 3 SUPERNOVA study show that the company’s investigational long-acting antibody (LAA) sipavibart ...

Johnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of bispecific immunology ...

Thermo Fisher Scientific has put forward a DNA-based test it says can offer much more precise identification of blood and its ...

Sanofi is betting $80 million upfront on a GSK castoff ahead of a phase 3 readout. Fulcrum Therapeutics took the other side ...

Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline ...